Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Pravastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Pravastatin. |
| Lovastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Lovastatin. |
| Cerivastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Cerivastatin. |
| Simvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Simvastatin. |
| Atorvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Atorvastatin. |
| Fluvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Fluvastatin. |
| Rosuvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Rosuvastatin. |
| Mevastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Mevastatin. |
| Pitavastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Raltegravir is combined with Pitavastatin. |
| Pantoprazole | Pantoprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Omeprazole | Omeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Lansoprazole | Lansoprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Esomeprazole | Esomeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Rabeprazole | Rabeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dexlansoprazole | Dexlansoprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dexrabeprazole | Dexrabeprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Ilaprazole | Ilaprazole can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Vonoprazan | Vonoprazan can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Rifabutin | The serum concentration of Raltegravir can be decreased when it is combined with Rifabutin. |
| Sucralfate | Sucralfate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bentoquatam | Bentoquatam can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium sulfate | Magnesium sulfate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium salicylate | Magnesium salicylate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Kaolin | Kaolin can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc | Zinc can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc trihydroxide | Zinc trihydroxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc Substituted Heme C | Zinc Substituted Heme C can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Potassium alum | Potassium alum can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Polaprezinc | Polaprezinc can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc oxide | Zinc oxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc sulfate | Zinc sulfate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium chloride | Magnesium chloride can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum chloride | Aluminum chloride can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium citrate | Magnesium citrate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc citrate | Zinc citrate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc picolinate | Zinc picolinate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminum sulfate | Aluminum sulfate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc gluconate | Zinc gluconate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bentonite | Bentonite can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium aspartate | Magnesium aspartate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Montmorillonite | Montmorillonite can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium gluconate | Magnesium gluconate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium orotate | Magnesium orotate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acetylcysteine zinc | Acetylcysteine zinc can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc ascorbate | Zinc ascorbate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc acetate | Zinc acetate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc glycinate | Zinc glycinate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium | Magnesium can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium levulinate | Magnesium levulinate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium lactate | Magnesium lactate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc chloride | Zinc chloride can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc sulfate, unspecified form | Zinc sulfate, unspecified form can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Zinc cation | Zinc cation can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nelfinavir | The metabolism of Raltegravir can be increased when combined with Nelfinavir. |
| Phenytoin | The metabolism of Raltegravir can be increased when combined with Phenytoin. |
| Desogestrel | The metabolism of Raltegravir can be increased when combined with Desogestrel. |
| Zidovudine | The metabolism of Raltegravir can be increased when combined with Zidovudine. |
| Ritonavir | The metabolism of Raltegravir can be increased when combined with Ritonavir. |
| Lamotrigine | The metabolism of Raltegravir can be increased when combined with Lamotrigine. |
| Carbamazepine | The metabolism of Raltegravir can be increased when combined with Carbamazepine. |
| Efavirenz | The metabolism of Raltegravir can be increased when combined with Efavirenz. |
| Primidone | The metabolism of Raltegravir can be increased when combined with Primidone. |
| Tipranavir | The metabolism of Raltegravir can be increased when combined with Tipranavir. |
| Ethinylestradiol | The metabolism of Raltegravir can be increased when combined with Ethinylestradiol. |
| Phenobarbital | The metabolism of Raltegravir can be increased when combined with Phenobarbital. |
| Testosterone propionate | The metabolism of Raltegravir can be increased when combined with Testosterone propionate. |
| Rifampin | The serum concentration of Raltegravir can be decreased when it is combined with Rifampicin. |
| Amprenavir | The serum concentration of Raltegravir can be decreased when it is combined with Amprenavir. |
| Fosamprenavir | The serum concentration of Raltegravir can be decreased when it is combined with Fosamprenavir. |
| Magnesium oxide | Magnesium oxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium bicarbonate | The serum concentration of Raltegravir can be decreased when it is combined with Sodium bicarbonate. |
| Aluminum hydroxide | Aluminum hydroxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium carbonate | The serum concentration of Raltegravir can be decreased when it is combined with Calcium carbonate. |
| Magaldrate | Magaldrate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium hydroxide | Magnesium hydroxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium trisilicate | Magnesium trisilicate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium carbonate | Magnesium carbonate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bismuth subnitrate | The serum concentration of Raltegravir can be decreased when it is combined with Bismuth subnitrate. |
| Magnesium silicate | Magnesium silicate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aluminium acetoacetate | Aluminium acetoacetate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Hydrotalcite | Hydrotalcite can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Magnesium peroxide | Magnesium peroxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Almasilate | The serum concentration of Raltegravir can be decreased when it is combined with Almasilate. |
| Aluminium glycinate | Aluminium glycinate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Aloglutamol | Aloglutamol can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcium silicate | The serum concentration of Raltegravir can be decreased when it is combined with Calcium silicate. |
| Aluminium phosphate | Aluminium phosphate can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Leuprolide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Raltegravir. |
| Somatotropin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Raltegravir. |
| Infliximab | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Raltegravir. |
| Daptomycin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Raltegravir. |
| Cyclosporine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cyclosporine is combined with Raltegravir. |
| Baclofen | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Raltegravir. |
| Sildenafil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Raltegravir. |
| Cladribine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Raltegravir. |
| Pamidronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Raltegravir. |
| Mefloquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Raltegravir. |
| Tacrine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Raltegravir. |
| Carbimazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Raltegravir. |
| Trimethoprim | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Raltegravir. |